{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:23:39Z","timestamp":1770333819257,"version":"3.49.0"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,12,25]],"date-time":"2019-12-25T00:00:00Z","timestamp":1577232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Despite an increased risk of atherosclerotic cardiovascular disease (<jats:styled-content style=\"fixed-case\">ASCVD<\/jats:styled-content>) in people living with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">PLWH<\/jats:styled-content>), a gap in statin\u00a0prescribing practices has been described for statin\u2010eligble\u00a0<jats:styled-content style=\"fixed-case\">PLWH<\/jats:styled-content> and uninfected patients. Few data have become available characterizing this gap since the publication of the 2013 American College of Cardiology\/American Heart Association lipid guidelines.\u00a0The objective of this study was to characterize statin prescribing rates for eligible PLWH compared to uninfected adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective, comparative analysis of patients seen at two clinics in an urban, academic medical system between February 2017 and September 2017. Patients who qualified for one of the statin benefit groups were included: those with a history of clinical <jats:styled-content style=\"fixed-case\">ASCVD<\/jats:styled-content>, low\u2010density lipoprotein cholesterol\u00a0\u2265\u00a0190\u00a0mg\/dL, diabetes\u00a0mellitus, or 10\u2010year <jats:styled-content style=\"fixed-case\">ASCVD<\/jats:styled-content> risk score\u00a0\u2265\u00a07.5%. Patients &lt;\u00a021\u00a0years old or without a lipid panel within 3\u00a0years were excluded. The primary outcome was the percentage of <jats:styled-content style=\"fixed-case\">PLWH<\/jats:styled-content> prescribed a statin compared to uninfected patients. Predictors associated with receiving a statin were analysed using a logistic regression model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine hundred and eight <jats:styled-content style=\"fixed-case\">PLWH<\/jats:styled-content> and 2239 uninfected patients met the study criteria. A difference in statin prescribing rates was observed between <jats:styled-content style=\"fixed-case\">PLWH<\/jats:styled-content> and uninfected patients (44% versus 56%, respectively; adjusted odds ratio\u00a0(OR) 0.79; 95% confidence interval (CI) 0.66\u20130.94). However, only in the 10\u2010year <jats:styled-content style=\"fixed-case\">ASCVD<\/jats:styled-content> risk group were the rates significantly different (24% for PLWH versus 36% for uninfected patients; adjusted OR 0.68; 95% CI 0.5\u20130.92). <jats:styled-content style=\"fixed-case\">PLWH<\/jats:styled-content> more often received a medium\u2010intensity statin and uninfected patients more often received a high\u2010intensity statin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">PLWH<\/jats:styled-content> with <jats:styled-content style=\"fixed-case\">ASCVD<\/jats:styled-content> risk were less likely to be prescribed a statin compared to uninfected patients. Additional analyses are needed to investigate reasons for the statin prescribing\u00a0gap and appropriateness of lipid agent selection in both study populations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12794","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T01:28:58Z","timestamp":1577323738000},"page":"135-141","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparing rates of statin therapy in eligible patients living with <scp>HIV<\/scp> versus uninfected patients"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8924-7947","authenticated-orcid":false,"given":"AL","family":"Blackman","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Sciences University of Maryland School of Pharmacy Baltimore MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0957-8197","authenticated-orcid":false,"given":"NS","family":"Pandit","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Sciences University of Maryland School of Pharmacy Baltimore MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KJ","family":"Pincus","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Sciences University of Maryland School of Pharmacy Baltimore MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,12,25]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000510"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-015-0105-8"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-017-0651-4"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1754"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit508"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003371"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062360"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/649897"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830fe35e"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/521935"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000540"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.002"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw289"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005995"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000360"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2015.1099602"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2017.0304"},{"key":"e_1_2_5_21_1","unstructured":"AlthoffKN HorbergMA EronJJet\u00a0al.The large gap between statin eligibility and prescription among HIV+ in North America. Conference on Retroviruses and Opportunistic Infections (CROI). February 13\u201316 2017.Seattle WA. Abstract 619."},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007107"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001454"},{"key":"e_1_2_5_24_1","unstructured":"LarsonDT WonSH GanesanAet\u00a0al.Statin use and cardiovascular disease mitigation among persons living with HIV. Conference on Retroviruses and Opportunistic Infections (CROI). March 4\u20137 2018.Boston MA. Abstract 705."},{"key":"e_1_2_5_25_1","unstructured":"AliN PrestiR PowderlyWG EscotaG.Statin utilization among human\u2010immunodeficiency virus (HIV)\u2010infected individuals based on the 2013 American College of Cardiology and American Heart Association (ACC\/AHA) blood cholesterol guideline. ID Week. October 5 2017.San Diego CA."},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-016-0893-z"},{"key":"e_1_2_5_27_1","unstructured":"ClinicalTrials.gov [Internet].Identifier NCT02344290 Evaluating the use of pitavastatin to reduce the risk of cardiovascular disease in HIV\u2010infected adults (REPRIEVE); 2015 Jan 22 [cited 2018 Jun 15].Bethesda (MD):National Library of Medicine (US). Available from:http:\/\/clinicaltrials.gov\/ct\/show\/NCT00287391?order=1."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12794","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12794","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.12794","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T20:57:01Z","timestamp":1694033821000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,25]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/hiv.12794"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12794","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,25]]},"assertion":[{"value":"2019-07-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}